Literature DB >> 26722062

Clinicopathological Features of Surgically-resected Biliary Tract Cancer Following Chemo-radiation Therapy.

Shogo Kobayashi1, Kunihito Gotoh2, Hidenori Takahashi2, Hirofumi Akita2, Shigeru Marubashi2, Terumasa Yamada2, Teruki Teshima3, Kinji Nishiyama3, Masahiko Yano2, Hiroaki Ohigashi2, Osamu Ishikawa2, Masato Sakon2.   

Abstract

AIM: We retrospectively investigated surgery following chemo-radiation in patients with biliary tract cancer (BTC) treated at our Institution. PATIENTS AND METHODS: Among 339 patients, 44 patients underwent chemo-radiation prior to surgery. Chemo-radiation entailed 2-3 months of standardized chemotherapy and 50-60 Gy radiation at the main tumor and regional and para-aortic lymph nodes.
RESULTS: Thirty-one BTC cases were classified as initially resectable (IR) and 13 as initially un-resectable (UR). Eighty percent of the BTCs were diagnosed as extrahepatic bile duct cancers. Gemcitabine (1,000 mg/m(2)) and radiation was used to treat 59% of patients. Thirty percent of patients underwent hemi-hepatectomy, and 50% underwent pancreatoduodenectomy. The R0 resection rate was 90% among IR and 54% among UR, and 3-year survival rates were 82% for IR and 17% for UR, respectively.
CONCLUSION: This retrospective analysis suggests that surgery after chemoradiation may contribute to R0 resection rate and survival for initially resectable BTC. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Biliary tract cancer; chemo-radiation; conversion; neoadjuvant treatment

Mesh:

Year:  2016        PMID: 26722062

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Outcomes After Radio(chemo)therapy for Non-Metastatic Bile Duct Cancer.

Authors:  Louisa Bolm; Lukas Kaesmann; Tobias Bartscht; Steven E Schild; Dirk Rades
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

2.  Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma.

Authors:  Ryusei Matsuyama; Ryutaro Mori; Yohei Ota; Yuki Homma; Yasuhiro Yabusita; Seigo Hiratani; Takashi Murakami; Yu Sawada; Kentaro Miyake; Yasuhiro Shimizu; Takafumi Kumamoto; Itaru Endo
Journal:  Ann Surg Oncol       Date:  2022-01-07       Impact factor: 5.344

3.  Conversion surgery for initially unresectable extrahepatic biliary tract cancer.

Authors:  Moon Young Oh; Hongbeom Kim; Yoo Jin Choi; Yoonhyeong Byun; Youngmin Han; Jae Seung Kang; Heeju Sohn; Jung Min Lee; Wooil Kwon; Jin-Young Jang
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.